Core Laboratories (NYSE: CLB ) is expected to report Q3 earnings on Oct. 17. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Core Laboratories's revenues will grow 5.6% and EPS will grow 10.0%.
The average estimate for revenue is $244.3 million. On the bottom line, the average EPS estimate is $1.10.
Last quarter, Core Laboratories reported revenue of $247.0 million. GAAP reported sales were 9.4% higher than the prior-year quarter's $225.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.16. GAAP EPS of $1.11 for Q2 were 34% higher than the prior-year quarter's $0.83 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 36.7%, 410 basis points better than the prior-year quarter. Operating margin was 30.4%, 460 basis points better than the prior-year quarter. Net margin was 21.4%, 350 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $973.0 million. The average EPS estimate is $4.45.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 548 members out of 558 rating the stock outperform, and 10 members rating it underperform. Among 122 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 120 give Core Laboratories a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Core Laboratories is hold, with an average price target of $134.02.
Are you missing a big story in the energy space? Read about "One Stock to Own Before Nat Gas Act 2011 Becomes Law." Click here for instant access to this free report.